4-基氧哌啶乙酸盐酸盐 | 1187930-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-基氧哌啶乙酸盐酸盐
• 英文名称: (Piperidin-4-yloxy)-acetic acid hydrochloride
• 英文别名: 2-piperidin-4-yloxyacetic acid;hydrochloride
• CAS: 1187930-35-3
• 化学式: C7H14ClNO3
• mdl: MFCD11858443
• 分子量: 195.64
• InChiKey: CKZMPJRVAMCLER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.23
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  58.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Process for the preparation of mixed anhydrides
  申请人：——

  公开号：US20020077481A1

  公开（公告）日：2002-06-20

  The present invention is concerned with an improved process for the manufacture of mixed anhydrides. The process comprises adding an adjuvant base to a mixture of acid and reactive acid derivative. It is especially suitable for use in the synthesis of peptides and/or for the manufacture of pharmaceutically active substances or corresponding intermediates.

  本发明涉及一种改进的混合酸酐制造过程。该过程包括向酸和反应性酸衍生物的混合物中添加辅助碱。它特别适用于合成肽和/或制造药用活性物质或相应中间体。
• NOVEL DIPIPERIDINE DERIVATIVE
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0706999A1

  公开（公告）日：1996-04-17

  The present invention relates to an novel dipiperidine derivative represented by formula (1), or a pharmaceutically acceptable salt thereof; wherein R¹ represents a hydrogen atom or a lower alkyl group; Y represents a single bond or an oxygen atom; n represents 1, 2 or 3; W represents a methylene group or an oxygen atom; R² represents a hydrogen atom or a carboxyl modifying group which can be eliminated in vivo; X¹ and X³ are the same or different and each represents a hydrogen atom or a lower alkyl group. This compound is useful as platelet aggregation inhibitors, cancer metastasis inhibitors, wound remedies or bone resorption inhibitors.

  本发明涉及一种由式（1）表示的新型二哌啶衍生物或其药学上可接受的盐； 其中，R¹代表氢原子或低级烷基；Y代表单键或氧原子；n代表1、2或3；W代表亚甲基或氧原子；R²代表氢原子或可在体内消除的羧基修饰基团；X¹和X³相同或不同，各自代表氢原子或低级烷基。 这种化合物可用作血小板聚集抑制剂、癌症转移抑制剂、伤口治疗剂或骨吸收抑制剂。
• 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP3196200A1

  公开（公告）日：2017-07-26

  [Problem] To provide a compound useful as an active ingredient in a pharmaceutical composition for treating bladder storage disorders, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors of the present invention have discovered that a 2-aminothiazole derivative exhibits an excellent muscarinic M3 receptor positive allosteric modulator activity, and has potential as a preventative or therapeutic agent against bladder and urinary tract diseases to which bladder contraction mediated by muscarinic M3 receptors contributes. The 2-aminothiazole derivative or salt thereof has potential as a preventative or therapeutic agent against bladder and urinary tract diseases such as, for example, dysuria including underactive bladder, and to which bladder contraction mediated by muscarinic M3 receptors contributes.

  [问题]提供一种化合物，作为药物组合物中的活性成分，用于治疗膀胱储尿障碍、排尿困难、下尿路疾病等。[解决方案]本发明的发明者发现，一种 2-氨基噻唑衍生物表现出优异的毒蕈碱 M3 受体正异位调节剂活性，具有作为膀胱和尿路疾病预防或治疗剂的潜力，膀胱和尿路疾病是由毒蕈碱 M3 受体介导的膀胱收缩造成的。2- 氨基噻唑衍生物或其盐具有预防或治疗膀胱和尿路疾病的潜力，例如，排尿困难，包括膀胱活动不足，而毒蕈碱 M3 受体介导的膀胱收缩是导致这些疾病的原因。
• Novel isoxazoline fibrinogen receptor antagonists
  申请人：——

  公开号：US20020082253A1

  公开（公告）日：2002-06-27

  Fibrinogen receptor antagonists of the formula: 1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

  式中的纤维蛋白原受体拮抗剂： 1 公开了用于抑制纤维蛋白原与血小板结合和抑制血小板聚集的纤维蛋白原受体拮抗剂。
• 2-AMINOTHIAZOLE DERIVATIVES OR SALT THEREOF AS MUSCARINIC M3 LIGANDS FOR THE TREATMENT OF BLADDER DISEASES
  申请人：Astellas Pharma Inc.

  公开号：EP3196200B1

  公开（公告）日：2019-05-08